DOCSLIB.ORG

2 Adrenergic Agonist Reversal Agents in the Horse

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2 Adrenergic Agonist Reversal Agents in the Horse DRUGS AND ANESTHESIA Review of Fatalities and Adverse Reactions After Administration of ␣-2 Adrenergic Agonist Reversal Agents in the Horse David B. Scofield, DVM; Dana L. Alexander, BS; Robert P. Franklin, DVM, Diplomate ACVIM; and Joseph J. Bertone, DVM, MS, Diplomate ACVIM Elective reversal of ␣-2 adrenergic receptor agonist sedation with either tolazoline or yohimbine is not without serious risk of idiosyncratic and potentially fatal consequences in the horse; as evidenced by clinical reports of drug reaction and possible death resulting from administration of tolazoline or yohimbine to reverse the effects of ␣-2 agonist sedation for veterinary procedures in the horse. Au- thors’ addresses: Equine Reproduction Laboratory, Colorado State University, Fort Collins, Colo- rado 80523 (Scofield); Weatherford Equine Medical Center, Weatherford, Texas 76088 (Franklin); and Western College of Veterinary Medicine, Pomona, California 91766 (Alexander and Bertone); e-mail: scofi[email protected]. © 2010 AAEP. 1. Introduction antagonize the effects of ␣-2 agonist sedatives. Selective ␣-2 adrenergic agonist drugs, such as xy- Therapeutic doses in horses may cause peripheral lazine HCl,a detomidine,b and romifidine,c represent vasodilation, which clinically leads to a transient commonly used sedatives and pre-anesthetics in increase in heart rate.2 Toxicity studies report dos- equine practice. These drugs are sometimes re- ages of five times the labeled dose in the horse may versed with ␣-2 adrenergic antagonists such as yo- cause increased gastric secretions, hyperperistalsis, himbine,d atipamezole,e and tolazoline.f Tolazoline flatulence, mild colic, or transient diarrhea.3 These is the only labeled product for the equid; therefore, same overdoses could lead to ventricular arrhyth- use of either yohimbine or atipamezole constitutes mias with prolonged QRS complexes and resultant as extra-label drug use. These reversal agents are death.3 ␣-2 Antagonists have been recommended deemed as safe pharmacologic products. Anecdotal as prokinetics because of their ability to counteract information, however, suggests that these products sympathetic outflow related to endotoxin and noci- can have significant adverse side effects in some cases. ceptive stimuli.4 Tolazoline produces strong peripheral vasodila- Anecdotal reports of deaths associated with tola- tion with sympathetic blocking and histamine- zoline reversal have created concern regarding the like actions.1 The drug competitively binds to ␣-1 safety of this drug.5 Sinus bradycardia, second-de- and ␣-2 adrenergic receptors, allowing the drug to gree atrioventricular block, and brief periods of si- NOTES 44 2010 ր Vol. 56 ր AAEP PROCEEDINGS DRUGS AND ANESTHESIA nus arrest occurred after rapid IV administration of Table 1. Summary of 18 Respondent Case Outcomes in Terms of Drug tolazoline (1 mg/kg) in five of six xylazine-sedated Use and Outcome 6 calves. A case of suspected idiosyncratic tolazo- Number of Compounded line reaction in a llama has been reported in which Respondents Outcome Products the patient exhibited generalized weakness, sei- zures, dyspnea, severe hypotension, tachycardia, Tolazoline 7 4 deaths None and diarrhea after receiving tolazoline.7 Both tola- Yohimbine 11 9 deaths 6 compounded products; zoline and yohimbine, when administered IV, will ϳ 3 labeled canine increase ventricular heart rate for 30 min after products; 8 injection. 2 undetermined In dogs, yohimbine blocks central ␣-2 adrenergic products receptors and can cause tachycardia, elevated blood pressure, and stimulation to the central nervous system (CNS).9 Yohimbine also blocks peripheral ␣-2 receptors found in the cardiovascular system, from hand walking to the administration of epineph- genitourinary system, gastrointestinal tract, adi- rine via IM injection, dexamethasone IV, and pred- pose tissue, and platelets, which can manifest clin- nisolone sodium succinate IV. Although these ically as muscle tremors, tachypnea, and hyperemic resuscitation efforts and pharmacologic interven- mucous membranes.9 tions were attempted, none clearly altered the out- Administration of ␣-2 adrenergic antagonists to come for the patient. reverse sedation has resulted in reported idiosyn- Nine of 18 patients were sedated with ␣-2 adren- cratic reactions in non-equid species. Animals ergic agonists for dental procedures. Other proce- have died after receiving rapid IV overdoses of yo- dures performed requiring sedation included IV himbine, atipamezole, or tolazoline.10 A 1-yr-old catheter placement, foot trimming, trailer loading, female polar bear (Ursus maritimus) immobilized laceration repair, and endoscopy. Three respon- with medetomidine-zolazepam-tiletamine died shortly dents did not report a specific procedure during se- after reversal from anesthesia with atipamezole ad- dation. Seven respondents reported injections of ministered IV.11 antagonists at or below the recommended dosages, The intent of this paper is to document adverse whereas 11 respondents did not provide dosage reactions and serious complications encountered information. when using the ␣-2 adrenergic antagonists tolazo- line and yohimbine to reverse common ␣-2 adrener- 4. Discussion gic agonists xylazine, detomidine, and romfidine in A high number of respondents (13/18) reported ulti- the horse. mate death of the animal in the immediate time frame of administering the reversal agent. All 2. Materials and Methods deaths attributed to tolazoline administration were Case reports of adverse reactions to administration with the product labeled for equine use. Although of either tolazoline or yohimbine for ␣-2 agonist re- five yohimbine reactions occurred with compounded versal were solicited from the AAEP List Serve and products, a Food and Drug Administration-approved Equine Clinician’s List Serve in early 2010. Respon- canine product (used off-label) was used in three dents were asked for patient signalment, medical cases. Compounding pharmacies have the ability problems, all pharmacologic agents administered, to alter certain characteristics of the drug such as nature of reaction, interventions attempted, out- concentration, delivery vehicles, pH, and storage re- come of situation, and any postmortem findings if quirements. In turn, each compounded product applicable. All data points were not obtained in all may, in fact, have different components that could cases in the series because of lack of available lead to reactions. Differences in pH, shelf life, sol- records in several instances. ubility, or preservatives from an approved product Additional information regarding the type of drug may alter the actions of the drug in vivo and in turn used, compounded or labeled product, was incor- potentiate adverse side effects. Compounded prod- porated as available. Data were compiled and are uct drug concentrations were examined post hoc in presented in Tables 1 and 2. two cases. Results supported an appropriate con- centration of yohimbine in compounded products, 3. Results although this does not exclude a reaction to the Briefly, 18 total responses were returned to the au- vehicle itself. thors. Of the 18 cases reported via email, mail, and The cause of negative reaction or death in this telephone conversations, there were 16 horses com- case series cannot be definitively attributed to the prised of various breeds, 4 mo to 24 yr of age, 1 administration of tolazoline or yohimbine. Circum- miniature Donkey, and 1 adult horse of unknown stantial evidence does support an adverse drug re- age. Of the 18 responses, 13 animals died despite action. Other possible causes include intracarotid intervention and resuscitation efforts (Table 2). injection, anaphylaxis, overdosage, confounding Five animals recovered with interventions varying medical issues, or unrelated cardiovascular event. AAEP PROCEEDINGS ր Vol. 56 ր 2010 45 46 2010 Table 2. Summary of All Respondent Data With All Provided Information DRUGS AND ANESTHESIA ր Nature of ␣ ␣ Vol. 56 Signalment Procedure Medical Problems Agonist Antagonist Reaction Intervention Outcome Postmortem Notes Male intact 3-yr- IV catheter ϳ7-day history of 10 mg IM Detomidine 100 mg Tolazoline Reaction occurred 250 mg IV flunixin Rose to feet N/A Continued treatment old miniature placement for broncho- (12 hours prior to IV slowly within 15 meglumine and within 20 for ր donkey; ϳ250 kg treatment of pneumonia reaction); and minutes. 500 mg solu- minutes, no bronchopneumonia; AAEP PROCEEDINGS broncho- evening dose of Tachycardia, delta cortef; 5 l significant tolazoline was pneumonia ceftiofur tachypneia, IV fluids post reaction given IV slowly blanched abnormalities over 30 seconds. mucus membranes, and sweating were observed. 6-yr-old Quarter Routine dental No known problems 5 mg IV Detomidine Yohimbine Gelding unstable Attempted Died N/A Quality control Horse Bay procedure (unknown dose) on feet. dexamethasone concentration of gelding and epinephrine yohimbine correct; administration Compounded product 16-yr-old Routine dental No known problems 5 mg Detomidine IV Yohimbine Mild ataxia 3 to 5 Stabilized within 5 Uneventful N/A Quality control found Warmblood procedure (unknown dose) minutes post min concentration of mare reversal yohimbine correct; Compounded product 5-yr-old Quarter Routine dental No known problems 250 mg Xylazine IV Yohimbine Tachypnea and Handwalked for 20 Uneventful N/A N/A Horse Bay procedure (unknown dose) injected mucus min and stable gelding membranes 6-yr-old Morgan Unknown Unknown Unknown 30 mg IV Immediate None Died
Load more

Recommended publications
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • Adrenoceptors Regulating Cholinergic Activity in the Guinea-Pig Ileum 1978) G.M
    - + ! ,' Br. J. Pharmac. (1978), 64, 293-300. F'(O t.,," e reab- ,ellular PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC _-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM 1978) G.M. Departmentof Pharmacology,Allen and HzmburysResearchLimited, Ware, Hertfordshire,SG12 ODJ I The presynaptic ct-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to at-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ! ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch i response; the maximum inhibition obtained was 80 to 95_o of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 lag/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine.
    [Show full text]
  • Drug Code List Version 11.2 Revised 9/11/17 List Will Be Updated Routinely
    Drug Code List Version 11.2 Revised 9/11/17 List will be updated routinely Disclaimer: For drug codes that require an NDC, coverage depends on the drug NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service. Note: Physician/Facility-administered medications are reimbursed using the Centers for Medicare and Medicaid Services (CMS) Part B Drug pricing file found on the CMS website--www.cms.hhs.gov. In the absence of a fee, pricing may reflect the methodolgy used for retail pharmacies. Highlights represent updated material for each specific revision of the Drug Code List. Code Description Brand Name NDC NDC unit Category Service AC CAH P NP MW MH HS PO OPH HI IDT DC Special Instructions Requir of Limits OP OP F ed measure 90281 human ig, im Gamastan Yes ML Antisera NONE X X X X Closed 3/31/13. 90283 human ig, iv Gamimune, Yes ML Antisera NONE X X X X Closed 3/31/13. Cost invoice required with claim. Restricted to ICD-9 diagnoses codes 204.10 - 204.12, Flebogamma, 279.02, 279.04, 279.06, 279.12, 287.31, and 446.1, and must be included on claim form, effective 10/1/09. Gammagard 90287 botulinum antitoxin N/A Antisera Not Covered 90288 botulism ig, iv No ML NONE X X X X Requires documentation and medical review 90291 cmv ig, iv Cytogam Yes ML Antisera NONE X X X X Closed 3/31/13. 90296 diphtheria antitoxin No ML NONE X X X X 90371 hep b ig, im Bayhep B, Yes ML Antisera NONE X X X X Closed 3/31/13.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 6290-6294,, December 1978 Neurobiology Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine (trieyclic antidepressants/antihistamine/neurotransmitter/amitriptyline) VINH TAN TRAN, RAYMOND S. L. CHANG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Julius Axelrod, August 30,1978 ABSTRACT The antihistamine [3H mepyramine binds to Male Sprague-Dawley rats (150-200 g) were killed by cer- HI histamine receptors in mammalian brain membranes. vical dislocation, their brains were rapidly removed and ho- Potencies of H1 antihistamines at the binding sites correlate mogenized with a Polytron for 30 min (setting 5) in 30 vol of with their pharmacological antihistamine effects in the guinea pig ileum. Specific [3Himepyramine binding is saturable with ice-cold Na/K phosphate buffer (50 mM, pH 7.5), and the a dissociation constant of about 4 nM in both equilibrium and suspension was centrifuged (50,000 X g for 10 min). The pellet kinetic experiments and a density of 10pmolper gram ofwhole was resuspended in the same volume of fresh buffer and cen- brain. Some tricyclic antidepressants are potent inhibitors of trifuged, and the final pellet was resuspended in the original secific [3Hmepamine binding. Regional variations of volume of ice-cold buffer by Polytron homogenization. Calf [3Hjmepyramine ing do not correlate with variations in brains were obtained from a local abattoir within 2 hr after the endogeneous histamine and histidine decarboxylase activity. death of the animals and transferred to the laboratory in ice- Histamine is a neurotransmitter candidate in mammalian brain cold saline.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Selection of Vasodilator Therapy for Severe Raynaud's Phenomenon by Sequential Arterial Infusion
    Ann Rheum Dis: first published as 10.1136/ard.44.3.151 on 1 March 1985. Downloaded from Annals of the Rheumatic Diseases, 1985; 44, 151-154 Selection of vasodilator therapy for severe Raynaud's phenomenon by sequential arterial infusion I JON RUSSELL AND RICHARD A WALSH From the Department of Medicine, Divisions of Clinical Immunology and Cardiology, the University of Texas Health Science Center at San Antonio, USA. SUMMARY Two young adults with impending gangrene due to persistent Raynaud's vasospasm were studied by sequential intra-arterial (IA) infusion of three vasodilatory drugs while arterial pressure and plethysmographic digital pulse volume were continuously monitored. The results of the IA infusion accurately predicted relief from vasospastic symptoms by oral drugs of the same class. This method may be useful in selecting the most effective vasodilator for patients with severe vasospasm. Key words: vasodilatation, tolazoline, hydralazine, diltiazem, phenoxybenzamine. Raynaud's phenomenon may occur as an isolated (PVR-4, Life Sciences Incorporated, Greenwich, copyright. problem or as one manifestation of a major clinical CT). This semisegmental plethysmograph uses an syndrome. The management of infrequent vasospas- air-containing cuff round the proximal or distal tic episodes can be as simple as avoidance of cold, phalanx to plot pulsations as wave fortns on a strip wearing of gloves, or windmilling the affected arm recorder.5 By inflating a second cuff round the to override the increased vascular tone.' For pa- proximal phalanx the pressure required to obliterate tients with very frequent or persistent attacks a pulsation at the distal phalanx was determined, and variety of chemotherapeutic remedies have been it was defined as the finger systolic pressure.
    [Show full text]
  • Redalyc.Effcts of Cassia Podocarpa Leaves Extracts on the Rat Ileum And
    Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas ISSN: 0717-7917 [email protected] Universidad de Santiago de Chile Chile Akomolafe, R.O.; Adeoshun, I.O.; Elujoba, A. A.; Iwalewa, E.O.; Ayoka, A.O. Effcts of cassia podocarpa leaves extracts on the rat ileum and colon (in vitro) Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas, vol. 3, núm. 3, mayo, 2004, pp. 52-57 Universidad de Santiago de Chile Santiago, Chile Available in: http://www.redalyc.org/articulo.oa?id=85630303 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative BLACPMA Vol. 3 Nº 3 Mayo 2004 52 ARTICULOS stimulated by the extract. With this results therefore, C. podocarpa leaves could be EFFCTS OF CASSIA PODOCARPA substituted for C. acutifolia leaves as LEAVES EXTRACTS ON THE RAT vegetable laxative. ILEUM AND COLON (IN VITRO) KEY WORDS: Motility, Anthraquinone, Allosteric activation. 2* 1 R.O. AKOMOLAFE , I.O. ADEOSHUN , 3 4 A.A. ELUJOBA , E.O. IWALEWA RESUMEN: La etnofarmacología y los AND informes científicos indican el uso hojas de C. 1 A.O. AYOKA podocarpa como purgante. Este estudio intenta encontrar el efecto in vitro de su Recibido: 16 May 2003 infusión ácuosa (ACPL) y los methanolic Recibido corregido: 1 September 2003 (MCPL) en el intestines de ratas, usando Aceptado: 30 November 2003 hojas de C. acutifolia (ACAL y MCAL) como la norma de la referencia.
    [Show full text]
  • Xylazine Tolazoline
    United States Department of Agriculture Agricultural Marketing Service | National Organic Program Document Cover Sheet https://www.ams.usda.gov/rules-regulations/organic/national-list/petitioned Document Type: ☐ National List Petition or Petition Update A petition is a request to amend the USDA National Organic Program’s National List of Allowed and Prohibited Substances (National List). Any person may submit a petition to have a substance evaluated by the National Organic Standards Board (7 CFR 205.607(a)). Guidelines for submitting a petition are available in the NOP Handbook as NOP 3011, National List Petition Guidelines. Petitions are posted for the public on the NOP website for Petitioned Substances. ☒ Technical Report A technical report is developed in response to a petition to amend the National List. Reports are also developed to assist in the review of substances that are already on the National List. Technical reports are completed by third-party contractors and are available to the public on the NOP website for Petitioned Substances. Contractor names and dates completed are available in the report. Xylazine/Tolazoline Livestock 1 2 Identification of Petitioned Substance 3 4 Chemical Names: 43 5 Xylazine 44 Trade Names: 6 Xylazine 45 Xylazine 7 Xylazine Hydrochloride 46 AnaSed® LA 8 Xylazine Monohydrochloride 47 Rompun® 9 N-(2,6-Diphenylmethyl)-5,6-dihydro-4H-1,3- 48 TranquiVed Injection 10 thiazin-2-amine 49 X-Ject SA 11 N-(2,6-Diphenylmethyl)-5,6-dihydro-4H-1,3- 50 XylaMed™Celactal 12 thiazin-2-amine hydrochloride 51 13 52
    [Show full text]
  • Drugs, Poisons and Controlled Substances Act 1981
    1834 ANNO TRICESIMO ELIZABETHAE SECUNDAE REGINAE VICTORIA Drugs, Poisons and Controlled Substances Act 1981 No. 9719 An Act to re-enact with Amendments the Law relating to Drugs, Poisons and Controlled Substances, to amend the Health Act 1958 and the Crimes Act 1958 and for other purposes. [Assented to 12 January 1982] BE IT ENACTED by the Queen's Most Excellent Majesty by and with the advice and consent of the Legislative Council and the Legislative Assembly of Victoria in this present ParUament assembled and by the authority of the same as follows (that is to say): Short tiUe. 1. (1) This Act may be cited as the Drugs, Poisons and Controlled Substances y4cM981. Commenco- (2) The several provisions of this Act shall come into operation ment. on a day or on the respective days to be fixed by proclamation or successive proclamations of the Governor in Council published in the Government Gazette. Arrangement (3) This Act is divided into Parts and Divisions as follows: of Act. Part I.—Introductory and Transitional ss. 2-11. Part II.—Poisons and Controlled Substances ss. 12-55. Division 1—Classification s. 12. Division 2—Authorized Persons ss. 13-14. Division 1981 Drugs, Poisons and Controlled Substances No. 9719 2335 Division 3—Poisons Advisory Committee ss. 15-18. Division 4—Licensed Persons s. 19. Division 5—Special Poisons s. 20. Division 6—Industrial, Educational and Laboratory Permits s. 21. Division 7—Issue of Licences and Permits s. 22. Division 8—Manufacture and Sale of Poisons or . Controlled Substances ss. 23-30. Division 9—Trade or Proprietary Poisons s.
    [Show full text]
  • Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs
    DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 DMD FastThis Forward. article has not Published been copyedited on andSeptember formatted. The 7, final 2012 version as doi:10.1124/dmd.112.047068may differ from this version. DMD #47968 Mitigating the inhibition of human Bile Salt Export Pump by drugs: opportunities provided by physicochemical property modulation, in-silico modeling and structural modification Daniel J. Warner, Hongming Chen, Louis-David Cantin, J. Gerry Kenna, Simone Stahl, Clare L. Walker, Tobias Noeske. Department of Medicinal Chemistry, AstraZeneca R&D Montreal, Montreal, Quebec, H4S Downloaded from 1Z9, Canada (DJW, LDC) Computational Sciences, Discovery Sciences, AstraZeneca R&D Mölndal, Pepparedsleden dmd.aspetjournals.org 1, Mölndal 43183, Sweden (HC) Molecular Toxicology, Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK (JGK, SS, CLW) Global Safety Assessment, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, at ASPET Journals on October 10, 2021 Sweden (TN) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 This article has not been copyedited and formatted. The final version may differ from this version. DMD #47968 Inhibition of the human Bile Salt Export Pump by drugs. Corresponding author: Tobias Noeske Global Safety Assessment AstraZeneca R&D Mölndal S-431 83 Mölndal, Sweden Phone: +46-31-7064002 Mobile: +46-727-158344
    [Show full text]
  • PRESYNAPTIC O-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY in the GUINEA-PIG ILEUM
    Br. J. Pharmac. (1978), 64, 293-300. PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC o-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM G.M. DREW Department of Pharmacology, Allen and Hanburys Research Limited, Ware, Hertfordshire, SG12 ODJ 1 The presynaptic ax-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to a-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch response; the maximum inhibition obtained was 80 to 95% of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 jg/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine.
    [Show full text]